{"id":49533,"date":"2022-10-12T13:01:53","date_gmt":"2022-10-12T11:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-ravulizumab-cwvz-efficacy-data-at-ectrims-2022\/"},"modified":"2022-10-12T13:01:53","modified_gmt":"2022-10-12T11:01:53","slug":"alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-ravulizumab-cwvz-efficacy-data-at-ectrims-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-ravulizumab-cwvz-efficacy-data-at-ectrims-2022\/","title":{"rendered":"Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS\u00ae (ravulizumab-cwvz) efficacy data at ECTRIMS 2022"},"content":{"rendered":"
\n

\nResults from CHAMPION-NMOSD trial demonstrated zero relapses with a median treatment duration of 73 weeks<\/i><\/b>\n<\/p>\n

\nAdditional presentations will underscore debilitating emotional and physical toll of NMOSD on patients and caregivers, and highlight urgency to reduce disease burden<\/i><\/b>\n<\/p>\n

WILMINGTON, Del.–(BUSINESS WIRE)–Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26 to 28, 2022.\n<\/p>\n

\nData presented at the meeting will feature new insights from Alexion\u2019s complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses, including findings on the first and only long-acting C5 complement inhibitor, ULTOMIRIS\u00ae<\/sup> (ravulizumab-cwvz).\n<\/p>\n

\nMarc Dunoyer, Chief Executive Officer, Alexion, said: \u201cNMOSD relapses are unpredictable and often cause permanent disability, including blindness, paralysis and even premature death. Our data build on the established role of complement inhibition in managing NMOSD and reinforce our commitment to patient-centered innovation. Results from the CHAMPION-NMOSD trial highlight the potential for ULTOMIRIS to substantially reduce the risk of relapse and ease treatment burden for the community.\u201d\n<\/p>\n

\nRedefining NMOSD disease management<\/b>\n<\/p>\n

\nAn oral presentation will showcase results of the CHAMPION-NMOSD trial, which evaluated the safety and efficacy of ULTOMIRIS in adults with AQP4 Ab+ NMOSD, compared to the external placebo arm from the pivotal SOLIRIS\u00ae<\/sup> PREVENT clinical trial.\n<\/p>\n

\nThe data will show there were zero adjudicated on-trial relapses observed in patients with AQP4 Ab+ NMOSD with a median treatment duration of 73 weeks, representing a relapse risk reduction of 98.6% (p<0.0001) compared to the external placebo arm. The safety and tolerability of ULTOMIRIS in the CHAMPION-NMOSD trial were consistent with previous clinical studies and other approved indications.\n<\/p>\n

\nImproving understanding of the NMOSD patient experience<\/b>\n<\/p>\n

\nTwo poster presentations detail findings from qualitative interviews with NMOSD patients. This work helps to inform the scientific community about the immediate and lasting impact of relapses, including ability to work and participate in daily activities, mobility and pain as well as reliance on caregiver support.\n<\/p>\n

\nAlexion presentations during ECTRIMS 2022<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n\n
\n

\nLead author<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nAbstract title<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPresentation details<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPittock, SJ<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nEfficacy and safety of ravulizumab-cwvz in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nOral Presentation O051\n<\/p>\n

\nOctober 27, 2022\n<\/p>\n

\n10:05 CEST (4:05 EDT)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPittock, SJ<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nEfficacy subgroup analyzes from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPoster Presentation P010\n<\/p>\n

\nOctober 26, 2022\n<\/p>\n

\n16:30 CEST (10:30 EDT)\n<\/p>\n

\n\u00a0\n<\/p>\n

\nePoster Tour 5\n<\/p>\n

\nOctober 28, 2022\n<\/p>\n

\n14:00 CEST (8:00 EDT)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAllen, K<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nSensitivity analysis using propensity score methods for primary efficacy outcome in the CHAMPION-NMOSD trial\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPoster Presentation P012\n<\/p>\n

\nOctober 26, 2022\n<\/p>\n

\n16:30 CEST (10:30 EDT)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPalace, J<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nMortality estimates in patients with anti-aquaporin-4 autoantibody positive neuromyelitis optica spectrum disorder\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPoster Presentation P018\n<\/p>\n

\nOctober 26, 2022\n<\/p>\n

\n16:30 CEST (10:30 EDT)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nKielhorn, A<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nLong-term burden of relapse in patients with AQP4+ NMOSD: simulation study based on network meta-analysis\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPoster Presentation P019\n<\/p>\n

\nOctober 26, 2022\n<\/p>\n

\n16:30 CEST (10:30 EDT)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOsborne, B<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nActivity impairment and support needs in patients with neuromyelitis optica spectrum disorder\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nPoster Presentation P418\n<\/p>\n

\nOctober 27, 2022\n<\/p>\n

\n17:00 CEST (11:00 EDT)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBernitsas, E<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nUnderstanding the symptoms of patients with neuromyelitis optica spectrum disorder and their impact on patient\u2019s lives: a qualitative interview study\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nePoster Presentation EP0901\n<\/p>\n

\nOctober 26, 2022\n<\/p>\n

\n8:00 CEST (2:00 EDT)\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nINDICATION(S) & IMPORTANT SAFETY INFORMATION for ULTOMIRIS\u00ae (ravulizumab-cwvz)<\/b>\n<\/p>\n

\nWhat is ULTOMIRIS?<\/b>\n<\/p>\n

\nULTOMIRIS is a prescription medicine used to treat:\n<\/p>\n